High expression of XIAP and Bcl-2 may inhibit programmed cell death in glioblastomas

• Autor(a) principal: Tirapelli,Daniela Pretti da Cunha
• Data de Publicação: 2017
• Outros Autores: Lustosa,Isis Lacrose, Menezes,Sarah Bomfim, Franco,Indira Maynart, Rodrigues,Andressa Romualdo, Peria,Fernanda Maris, Marinho,Alexandre Magno da Nóbrega, Serafini,Luciano Neder, Carlotti Jr,Carlos Gilberto, Tirapelli,Luís Fernando
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Arquivos de neuro-psiquiatria (Online)
• Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2017001200875
• topic: glioblastoma; apoptosis; X-linked inhibitor of apoptosis protein; B-cell lymphoma 2

ABSTRACT Glioblastoma (GBM) is the most malignant glioma and represents 29% of all brain tumors. Tumorigenesis is intimately connected with characteristics acquired in the physiologic pathway of cellular death. Objective: In the present study, the expression of anti-apoptotic (XIAP and Bcl-2) and apoptotic (cytochrome C, caspase 9, APAF-1), caspase 3 and the Smac/DIABLO genes related to the apoptosis pathway were evaluated in 30 samples of glioblastoma. Methods: The gene expression was evaluated in 30 glioblastomas (WHO grade IV) and compared to 10 white matter control samples with real-time PCR. Results and Conclusion: There were higher expressions of XIAP (p = 0.0032) and Bcl-2 (p = 0.0351) in the glioblastoma samples compared to the control samples of normal brain. These results raise the question of whether Bcl-2 and XIAP genes can be responsible for the inhibition of programmed cell death in glioblastomas. Moreover, they provide additional information capable of allowing the development of new target therapy strategies.